• Citing Article List

    The journal uses Crossref Cited-by service counts times cited of published articles. Cited-by allows Crossref members to find out who is citing their content. This is the Citing Article List of “New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development”.
    No. Publication Date Citing Article
    1 2023 Jesse Lopes da Silva, Giselle de Souza Carvalho, Lucas Zanetti de Albuquerque, Fabiana Resende Rodrigues, Priscila Valverde Fernandes, Daniel Kischinhevsky, Andreia Cristina de Melo. Exploring Real-World HER2-Low Data in Early-Stage Triple-Negative Breast Cancer: Insights and Implications, Breast Cancer: Targets and Therapy. 2023; Volume 15: 337.  https://doi.org/10.2147/BCTT.S408743
    2 2024 Arianna Dri, Grazia Arpino, Giampaolo Bianchini, Giuseppe Curigliano, Romano Danesi, Michelino De Laurentiis, Lucia Del Mastro, Alessandra Fabi, Daniele Generali, Alessandra Gennari, Valentina Guarneri, Daniele Santini, Edda Simoncini, Claudio Zamagni, Fabio Puglisi. Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs), Cancer Treatment Reviews. 2024; 123: 102672102672.  https://doi.org/10.1016/j.ctrv.2023.102672
    3 2023 Weiru Chi, Bingqiu Xiu, Min Xiong, Xuliren Wang, Pei Li, Qi Zhang, Jianjing Hou, Yuting Sang, Xujie Zhou, Ming Chen, Shuyue Zheng, Liyi Zhang, Jingyan Xue, Yayun Chi, Jiong Wu. MNX1 Promotes Anti-HER2 Therapy Sensitivity via Transcriptional Regulation of CD-M6PR in HER2-Positive Breast Cancer, International Journal of Molecular Sciences. 2023; 25: 221.  https://doi.org/10.3390/ijms25010221
    4 2024 Ornella Garrone, Caterina A. M. La Porta. Artificial Intelligence for Precision Oncology of Triple-Negative Breast Cancer: Learning from Melanoma, Cancers. 2024; 16: 692.  https://doi.org/10.3390/cancers16040692
    5 2024 Komal Jhaveri, Frederik Marmé. Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer, Cancer Treatment Reviews. 2024; 123: 102670102670.  https://doi.org/10.1016/j.ctrv.2023.102670
    6 2023 Md Abdus Subhan, Vladimir P. Torchilin. Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate, Pharmaceutics. 2023; 15: 1242.  https://doi.org/10.3390/pharmaceutics15041242
    7 2023 Carmelo Laface, Francesco Giuliani, Assunta Melaccio, Maria Nicla Pappagallo, Anna Natalizia Santoro, Martina Perrone, Pierluigi De Santis, Chiara Guarini, Daniela Carrozzo, Palma Fedele. The Treatment Landscape of Elderly Patients with Hormone Receptor-Positive Her2 Negative Advanced Breast Cancer: Current Perspectives and Future Directions, Journal of Clinical Medicine. 2023; 12: 6012.  https://doi.org/10.3390/jcm12186012
    8 2023 Duygu Akca, Adrian Simon, Reinhard Buettner, Christiane Bruns, Wolfgang Schroeder, Thomas Zander, Florian Gebauer, Alexander Quaas. Syndecan‑1 expression is an independent favourable prognostic marker in oesophageal adenocarcinoma and represents a potential therapeutic target, Oncology Letters. 2023; 26: 356.  https://doi.org/10.3892/ol.2023.13942
    9 2023 Marta Tapia, Cristina Hernando, María Teresa Martínez, Octavio Burgués, Cristina Tebar-Sánchez, Ana Lameirinhas, Anna Ágreda-Roca, Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lluch, Begoña Bermejo, Pilar Eroles. Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies, Cancers. 2023; 15: 4522.  https://doi.org/10.3390/cancers15184522
    10 2023 Xuan Huang, Mengxuan Zhu, Ruoxue Chen, Junjie Ni, Wenrui Zhao, Song Li, Xiaoling Lu, Heng Jiao, Xin Cao. Innovative drugs promote precision cancer therapy, Clinical Cancer Bulletin. 2023; 2: 1.  https://doi.org/10.1007/s44272-023-00002-8
    11 2023 Joshua Hurwitz, Lucy Roxana Haggstrom, Elgene Lim. Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy, Pharmaceutics. 2023; 15: 2017.  https://doi.org/10.3390/pharmaceutics15082017
    12 2022 Ciaran Devoy, Yensi Flores Bueso, Mark Tangney. Understanding and harnessing triple-negative breast cancer-related microbiota in oncology, Frontiers in Oncology. 2022; 12: 1020121.  https://doi.org/10.3389/fonc.2022.1020121
    13 2024 Baohong Jiang, Sixuan Wu, Lijun Zeng, Yuanbin Tang, Lunqi Luo, Lianjie Ouyang, Wenjie Feng, Yeru Tan, Yuehua Li. Impact of NDUFAF6 on breast cancer prognosis: linking mitochondrial regulation to immune response and PD-L1 expression, Cancer Cell International. 2024; 24: 99.  https://doi.org/10.1186/s12935-024-03244-1
    14 2022 Yueyang Liu, Weiwei Gong, Sarah Preis, Julia Dorn, Marion Kiechle, Ute Reuning, Viktor Magdolen, Tobias F. Dreyer. A Pair of Prognostic Biomarkers in Triple-Negative Breast Cancer: KLK10 and KLK11 mRNA Expression, Life. 2022; 12: 1517.  https://doi.org/10.3390/life12101517
    15 2022 Desh Deepak Singh, Hae-Jeung Lee, Dharmendra Kumar Yadav. Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer, Frontiers in Pharmacology. 2022; 13: 1089066.  https://doi.org/10.3389/fphar.2022.1089066